The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer.

ABSTRACT:

Background

The hypoxia marker pimonidazole is a candidate biomarker of cancer aggressiveness. We investigated the transcriptional programme associated with pimonidazole staining in prostate cancer.

Methods

Index tumour biopsies were taken by image guidance from an investigation cohort of 52 patients, where 43 patients received pimonidazole before prostatectomy. Biopsy location within the index tumour was verified for 46 (88%) patients, who were included for gene expression profiling and immunohistochemistry. Two independent cohorts of 59 and 281 patients were used for validation.

Results

Expression of genes in proliferation, DNA repair and hypoxia response was a major part of the transcriptional programme associated with pimonidazole staining. A signature of 32 essent

SUBMITTER: Ragnum HB 

PROVIDER: S-EPMC4453458 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature